Fundz

Fundz Deep Dive

Everything you need to win Kyowa Kirin International and NewBridge Pharmaceuticals — in one platform.

Who to reach, what to say, and why now on Kyowa Kirin International and NewBridge Pharmaceuticals — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Kyowa Kirin International and NewBridge Pharmaceuticals — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Kyowa Kirin International and NewBridge Pharmaceuticals Enter Into Agreement to Improve Access to Medicines for Rare Disease Patients Across Middle East and North Africa

Aug 07, 2024•almost 2 years ago

Contract Type

agreement

Mount Lebanon GovernorateBiotechnologyHealth CarePharmaceutical

Description

Kyowa Kirin International (KKI) and NewBridge Pharmaceuticals have signed a Promotion and Distribution Agreement to distribute KKI's existing rare disease portfolio, including CRYSVITA® and POTELIGEO®, across the Middle East and North Africa. NewBridge will exclusively distribute the two products in several MENA countries and aims to support disease awareness, improve time to diagnosis, and enhance access to innovative treatments for rare and orphan diseases.

Company Information

Company

Kyowa Kirin International and NewBridge Pharmaceuticals

Location

Mount Lebanon Governorate, Lebanon

About

Kyowa Kirin International and NewBridge Pharmaceuticals have entered into an agreement to improve access to medicines for rare disease patients across the Middle East and North Africa.

Predictive Intelligence
Strategic

ML-powered predictions for Kyowa Kirin International and NewBridge Pharmaceuticals's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.